|
| |
| | Surgical versus medical treatment with <b>cyclooxygenaseb> inhibitors for symptomatic patent ductus arteriosus in preterm infants |
 | | Efficacy and toxicity of indomethacin and other <b>cyclooxygenaseb> inhibitor drugs have been explored extensively and many variations in dosage regimens have been reported in the literature (Yanowitz 1998; Ng 1997; Patel 2000; Van Overmeire 2000). |  | | Early closure of the ductus arteriosus may be achieved pharmacologically using <b>cyclooxygenaseb> inhibitors, or by surgery. |  | | The reviewers were surprised at the paucity of trials comparing surgical versus medical treatment with <b>cyclooxygenaseb> inhibitors for symptomatic PDA in preterm infants. |
|
http://www.nichd.nih.gov/cochrane/Malviya/MALVIYA.HTM
(5703 words)
|
|
| |
| | <b>Cyclooxygenaseb> Isoenzymes and Newer Therapeutic Potential for Selective COX-2 Inhibitors |
 | | <b>Cyclooxygenaseb> (COX), the enzyme that catalyses the synthesis of cyclic endoperoxides from arachidonic acid to form prostaglandins (PG), was isolated in 1976 and cloned in 1988 (1).This membrane-bound hemo- and glycoprotein has a molecular weight of 71 kDa, and is found in the greatest amounts in the endoplasmic reticulum of prostanoid forming cells (2). |  | | <b>Cyclooxygenaseb> (COX), also known as prostaglandin G/H synthase, is a membrane-bound enzyme responsible for the oxidation of arachidonic acid to prostaglandins that was first identified over 20 years ago. |  | | <b>Cyclooxygenaseb> 2 expression is increased in frontal cortex of Alzheimer 's disease brain. |
|
http://www.prous.com/journals/mf/sample/html/mf220291/mf220291.html
(3760 words)
|
|
| |
| | Chem406: Amanda Bruce - <b>Cyclooxygenaseb> |
 | | In contrast, COX-2 is only made under certain conditions and leads to the biosynthesis of prostaglandins triggering pain and inflammatory responses. |  | | The demand for NSAIDs without the negative side effects associated with aspirin has prompted researchers to explore the differences between the two isoforms in an attempt to develop drugs with COX-2 specificity. |  | | Aspirin, acetaminophen, and ibuprofin all belong to a class of drugs called non-steriodal anti-inflammatory drugs (NSAIDs), which act on the <b>cyclooxygenaseb> portion of the enzyme prostaglandin synthase. |
|
http://www.chem.uwec.edu/Webpapers_F98/bruce/bruce.html
(226 words)
|
|
| |
| | <b>Cyclooxygenaseb> Inhibitors |
 | | The guidance will be reviewed in the light of new evidence in May 2004. |  | | Practice Guideline [Publication Type]; Great Britain; <b>Cyclooxygenaseb> Inhibitors / therapeutic use; Arthritis / drug therapy; Anti-Inflammatory Agents, Non-Steroidal / therapeutic use; |  | | <b>Cyclooxygenaseb> Inhibitors / adverse effects; <b>Cyclooxygenaseb> Inhibitors / therapeutic use |
|
http://omni.ac.uk/browse/mesh/D016861.html
(395 words)
|
|
| |
| | How NSAIDs Work |
 | | The two forms of <b>cyclooxygenaseb> have equal molecular weights and are very similar in structure (Table 2). |  | | Nonsteroidal anti-inflammatory drugs work by interfering with the <b>cyclooxygenaseb> pathway (Figure 3). |  | | Perhaps acetaminophen is more specific to a third form of <b>cyclooxygenaseb>, a COX-3, which exists in the brain (35), accounting for the drugs analgesic and antipyretic abilities. |
|
http://elfstrom.com/arthritis/nsaids/actions.html
(952 words)
|
|
| |
| | eMedicine - <b>Cyclooxygenaseb> Deficiency : Article by John R Witherow, MD |
 | | Synonyms and related keywords: <b>cyclooxygenaseb> deficiency, COX deficiency, prostaglandin-endoperoxide synthase deficiency, PTGS deficiency, fatty acid <b>cyclooxygenaseb> deficiency, prostaglandin H synthase deficiency, PGH synthase deficiency, EC 1.14.99.1 deficiency, eicosanoid, seminal fluid, COX inhibition, COX-1, PTGS-1,COX-2, PTGS-2 |  | | Fuse I, Hattori A, Nagayama R: Characterization of platelet cytoplasmic Ca2+ mobilization in patients with congenital cyclo-oxygenase deficiency and with defective platelet aggregation to A23187. |  | | <b>Cyclooxygenaseb> (COX), also known as prostaglandin-endoperoxide synthase (PTGS), fatty acid COX, PGH synthase, and EC 1.14.99.1, is a key regulatory enzyme in the synthetic pathway of eicosanoid production. |
|
http://www.emedicine.com/med/topic3096.htm
(3454 words)
|
|
| |
| | <b>Cyclooxygenaseb>-2-Selective Inhibitors: Translating Pharmacology into Clinical Utility |
 | | Cyclooxygenases - Part 3: <b>Cyclooxygenaseb>-2-Selective Inhibitors: Translating Pharmacology into Clinical Utility |  | | <b>Cyclooxygenaseb> Inhibitors - Part 4: <b>Cyclooxygenaseb>-2-Selective Inhibitors: Translating Pharmacology into Clinical Utility |  | | Together with the lipoxygenases, <b>cyclooxygenaseb> (COX) enzymes play a key role in inflammation, pain, and other biologic processes. |
|
http://www.spineuniverse.com/displayarticle.php/article1543.html
(1443 words)
|
|
| |
| | Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in <b>Cyclooxygenaseb>-2-dependent Invasion -- Dohadwala et al. 277 (52): 50828 -- Journal of Biological Chemistry |
 | | The abbreviations used are: COX, <b>cyclooxygenaseb>; MMP, matrix metalloproteinase; NSCLC, nonsmall cell lung cancer; PGE2, prostaglandin E2; IBMX, 3-isobutyl-1-methylxanthine; dmPGE2, 16,16-dimethyl-prostaglandin E2; IL, interleukin; SFM, serum-free medium. |  | | In order to define the pathways responsible for COX-2-dependent induction of MMP-2, we determined the level of tumor MMP-2 |  | | COX-2 is known to be up-regulated in response |
|
http://www.jbc.org/cgi/content/full/277/52/50828
(2978 words)
|
|
| |
| | <b>Cyclooxygenaseb>-2 in the Kidney -- HARRIS 11 (12): 2387 -- Journal of the American Society of Nephrology |
 | | Blume C, Heise G, Muhlfeld A, Bach D, Schror K, Gerhardz CD, Grabensee B, Heering P: Effect of flosulide, a selective <b>cyclooxygenaseb> 2 inhibitor, on passive Heymann nephritis in the rat. |  | | 1, sham; 2, 1 wk after ablation; 3, 2 wk after ablation; 4, 3 wk after ablation. |  | | Harris RC, Badr KF: Recovery of prostaglandin synthesis in rat glomerular mesangial cells after aspirin inhibition: Induction of <b>cyclooxygenaseb> activity by serum and epidermal growth factor. |
|
http://www.jasn.org/cgi/content/full/11/12/2387
(2978 words)
|
|
| |
| | <b>Cyclooxygenaseb>-2---10 Years Later -- Hinz and Brune 300 (2): 367 -- Journal of Pharmacology And Experimental Therapeutics |
 | | <b>Cyclooxygenaseb>-2---10 Years Later -- Hinz and Brune 300 (2): 367 -- Journal of Pharmacology And Experimental Therapeutics |  | | Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT and Schmaier AH (2000) Thrombosis in patients with connective tissue diseases treated with specific <b>cyclooxygenaseb> 2 inhibitors. |  | | Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ and Wilson KT (1999) Increased expression and cellular localization of inducible nitric oxide synthase and <b>cyclooxygenaseb> 2 in Helicobacter pylori gastritis. |
|
http://jpet.aspetjournals.org/cgi/content/full/300/2/367
(2978 words)
|
|
| |
| | <b>Cyclooxygenaseb> in biology and disease -- Dubois et al. 12 (12): 1063 -- The FASEB Journal |
 | | Spangler, R. (1996) <b>Cyclooxygenaseb> 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. |  | | Yamamoto, T., and Nozaki-Taguchi, N. (1996) Analysis of the effects of <b>cyclooxygenaseb> (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. |  | | <b>Cyclooxygenaseb> in biology and disease -- Dubois et al. |
|
http://www.fasebj.org/cgi/content/full/12/12/1063
(7609 words)
|
|
| |
| | Antiangiogenic and Antitumor Activities of <b>Cyclooxygenaseb>-2 Inhibitors -- Masferrer et al. 60 (5): 1306 -- Cancer Research |
 | | Prognostic significance of vascular endothelial growth factor and <b>cyclooxygenaseb> 2 expression in patients receiving preoperative chemoradiation for esophageal cancer |  | | Interaction between epidermal growth factor receptor- and <b>cyclooxygenaseb> 2-mediated pathways and its implications for the chemoprevention of head and neck cancer |  | | <b>Cyclooxygenaseb> (COX)-2 Inhibitor Celecoxib Abrogates Activation of Cigarette Smoke-Induced Nuclear Factor (NF)-{kappa}B by Suppressing Activation of I-{kappa}B {alpha} Kinase in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of Cyclin D1, COX-2, and Matrix Metalloproteinase-9 |
|
http://cancerres.aacrjournals.org/cgi/content/abstract/60/5/1306
(2884 words)
|
|
| |
| | Introduction |
 | | The reaction catalyzed by <b>cyclooxygenaseb> results in the biosynthesis of prostaglandins from their arachadonic acid precursor. |  | | This page will look at the <b>cyclooxygenaseb>/aspirin interaction in depth as aspirin is the only NSAID to covalently modifies <b>cyclooxygenaseb>. |  | | The <b>cyclooxygenaseb> component prostaglandin synthase introduces four oxygen atoms onto the intermediate. |
|
http://www.chem.uwec.edu/Webpapers_F98/bruce/Pages/intro.html
(172 words)
|
|
| |
| | National Cancer Institute - <b>Cyclooxygenaseb> (COX) Inhibitors |
 | | NCI-Sponsored Trials of <b>Cyclooxygenaseb> (COX) Inhibitors for Cancer Prevention and Treatment |  | | <b>Cyclooxygenaseb> (COX) inhibitors are compounds that block <b>cyclooxygenaseb> enzymes, which are produced in response to inflammation and by precancerous and cancerous tissues. |  | | Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain and inflammation from many medical conditions by inhibiting two different COX enzymes called COX-1 and COX-2. |
|
http://www.cancer.gov/clinicaltrials/developments/COX-inhibitors-digest
(241 words)
|
|
|